Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)

Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)

NCT02999178 ·Status: COMPLETED ·Phase: PHASE3

Impact of Pre-transplant Anti-fibrotic Therapy for IPF Upon Lung Transplant Outcomes

NCT04316780 ·Status: COMPLETED

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321069 ·Status: COMPLETED ·Phase: PHASE3

Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

NCT05130970 ·Status: COMPLETED ·Phase: PHASE2

Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis

NCT04541680 ·Status: RECRUITING ·Phase: PHASE3

Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment

NCT02788474 ·Status: COMPLETED ·Phase: PHASE4

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

NCT03422068 ·Status: COMPLETED ·Phase: PHASE1

A Study to Test How Well a Medicine Called Nintedanib Helps People in China With Progressive Lung Fibrosis

NCT05065190 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of Nintedanib in the Treatment of Pulmonary Fibrosis in Patients With Moderate to Severe COVID -19

NCT04338802 ·Status: UNKNOWN ·Phase: PHASE2

A Treatment Protocol to Support the Care of Children and Adolescents With Fibrosing Interstitial Lung Disease (ILD)

NCT05624281 ·Status: NO_LONGER_AVAILABLE

Burden of Nintedanib Non-adherence Among Idiopathic Pulmonary Fibrosis (IPF) Patients

NCT05870956 ·Status: COMPLETED

The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19

NCT04619680 ·Status: COMPLETED ·Phase: PHASE4

Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis

NCT01619085 ·Status: COMPLETED ·Phase: PHASE3

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

NCT02579603 ·Status: COMPLETED ·Phase: PHASE4

An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis

NCT03573505 ·Status: TERMINATED ·Phase: PHASE2

A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT04419506 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02477709 ·Status: COMPLETED ·Phase: PHASE2

The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment Trial

NCT04161014 ·Status: UNKNOWN ·Phase: PHASE2

STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01371305 ·Status: COMPLETED ·Phase: PHASE2

A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast

NCT06238622 ·Status: RECRUITING ·Phase: PHASE3

A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment

NCT07036523 ·Status: RECRUITING ·Phase: PHASE2

Evaluation of Efficacy and Safety of PLN-74809 in Patients With Idiopathic Pulmonary Fibrosis

NCT04396756 ·Status: COMPLETED ·Phase: PHASE2

Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

NCT03939520 ·Status: COMPLETED ·Phase: PHASE4

Safety And Efficacy of BIBF 1120 in Idiopathic Pulmonary Fibrosis

NCT00514683 ·Status: COMPLETED ·Phase: PHASE2

A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood

NCT06241560 ·Status: RECRUITING ·Phase: PHASE2